Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
MEI Pharma Inc
0JW9Current price
3.12 USD
-0.023 USD (-0.73%)
Last closed
3.03 USD
Company
www.meipharma.com
ISIN
US55279B2025
Sector
Healthcare
Industry
Biotechnology
Exchange
London Exchange
Capitalization
20 321 722 USD
Yield for 12 month
-41.79 %
1Y
3Y
5Y
10Y
15Y
0JW9
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Address: 11455 El Camino Real, San Diego, CA, United States, 92130
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6 USDP/E ratio
0.7722Dividend Yield
–Current Year
+48 816 000 USD
Last Year
+40 697 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+47 001 000 USD
Last Year
+39 462 000 USD
Current Quarter
-86 000 USD
Last Quarter
-85 000 USD
Key Figures 0JW9
1 year
3 years
5 years
10 years
EBITDA
20 735 000 USD
Operating Margin TTM
PE Ratio
0.7722
Return On Assets TTM
12.4 %
PEG Ratio
20.6
Return On Equity TTM
61.27 %
Wall Street Target Price
6 USD
Revenue TTM
66 754 000 USD
Book Value
7.66 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
648 %
Dividend Yield
–
Gross Profit TTM
48 816 000 USD
Earnings per share
3.95 USD
Diluted Eps TTM
3.95 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
39.18 %
Dividend Analytics 0JW9
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0JW9
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
16.11.2023
Forward Annual Dividend Yield
0.38 %
Last Split Factor
1:20
Payout Ratio
32.23 %
Last Split Date
17.04.2023
Dividend Date
06.12.2023
Stock Valuation 0JW9
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
0.7722
Forward PE
–
Enterprise Value Revenue
1.3924
Price Sales TTM
0.3044
Enterprise Value EBITDA
-1.5797
Price Book MRQ
0.3956
Financials 0JW9
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0JW9
For 52 weeks
2.73 USD
6.91 USD
50 Day MA
3.18 USD
Shares Short Prior Month
16 077
200 Day MA
3.94 USD
Short Ratio
0.55
Shares Short
11 200
Short Percent
0.2 %
BeatStart